InMed Pharmaceuticals is a clinical stage company that specializes in researching and developing cannabinoid-based therapies. The company's lead product, INM-755, a topical cream, is currently undergoing Phase I clinical trials for the treatment of epidermolysis bullosa. In addition to this, InMed Pharmaceuticals is also working on developing cannabinoid treatments for various other diseases, including pain and ocular and dermatology diseases.